News Articles 111 - 120 of 160
A study from the University of Athens suggests a potentially synergistic effect of smoking and chronic HCV on the atherosclerotic process.
Researchers evaluated platelet microparticle (PMP) levels before and after treatment with pegylated-interferon-alfa and ribavirin in 28 chronic HCV patients compared with 20 non-alcoholic fatty liver disease (NAFLD) patients and 20 healthy volunteers.
Twenty-four of the HCV patients achieved sustained virological response (SVR). PMP levels were determined at baseline in HCV and NAFLD patients, and the volunteers, at end-of-treatment (EOT) and 24 weeks post-treatment (SVR24) in the HCV patients.
PMP levels at baseline were higher in the HCV than in the NAFLD patients and volunteers. Higher PMPs at baseline were observed in smokers than non-smokers with HCV. Among smokers from all groups, PMPs at baseline were higher in the HCV than the NAFLD patients or volunteers.
In the HCV patients, PMPs declined from baseline to both EOT and SVR24. Only HCV patients with SVR had a significant decline in PMPs from baseline to SVR24. PMPs at ΕΟΤ and SVR24 in all HCV patients were similar to PMPs in NAFLD patients and volunteers.
The researchers concluded that PMP levels are increased in HCV patients, particularly smokers, which further supports the atherosclerotic potential of HCV and suggests a potentially synergistic effect of smoking and HCV on the atherosclerotic process. Since PMP levels in HCV patients with SVR were similar to NAFLD patients and volunteers, the atherosclerotic potential of HCV seems to be abolished by effective antiviral treatment.
The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. Kanellopoulou T, Alexopoulou A, Kontopidou FN et al. Ann Gastroenterol. 2016 Apr-Jun;29(2):201-7
A study found that patients with compensated HCV cirrhosis who achieved a sustained virologic response (SVR) when treated with interferon (IFN) had a survival rate similar to the general population.
Researchers studied surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an IFN-based regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death.
Overall, 28 of 181 patients followed-up for a median period of 9.6 years died. The 10 and 20-year overall survival rates for the whole series were 90.9% and 62.9%, respectively. The number of expected deaths in the corresponding age and sex matched general population was 28.1, corresponding to a standardized mortality ratio (SMR) of 1.00, with an SMR for non-SVR patients of 3.85, for untreated of 3.01 and for decompensated of 6.70.
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Bruno S, Di Marco V, Lavarone M et al. J Hepatol. 2016 Mar 23 [Epub ahead of print]
A study in Taiwan found that high concentrations of arsenic in drinking water significantly increased the risk of hepatitis or cirrhosis in people without chronic viral hepatitis. However, the study also found that, in people with chronic viral hepatitis, lower levels significantly reduced the risk.
Researchers examined associations between exposure of arsenic in drinking water and risk of hepatitis and cirrhosis, and the interaction with chronic viral hepatitis, in 4,387 people living in the Lanyang Basin of northeastern Taiwan, where well water has an arsenic content that ranges from undetectable to 3590 μg/L.
The prevalence odds ratios in the overall study population for chronic hepatitis or cirrhosis for well water arsenic concentrations of =10 μg/L were 1.00 (reference), 0.93 for 10.1-49.9 μg/L, 1.24 for 50.0-99.9 μg/L, 0.98 for 100.0-299.9 and 1.86 for =300.0 μg/L.
Increasing levels of arsenic in drinking water were associated with increasing prevalence of chronic hepatitis or cirrhosis in residents who were seronegative for HBsAg and seronegative for anti-HCV, but not for seropositive for either HBsAg or anti-HCV.
In individuals who were seropositive for HBsAg or anti-HCV, there was an inverse association between hepatitis or cirrhosis and consumption of water with levels of arsenic =100.0μg/L. Among participants who were seropositive for HBsAg or anti-HCV, consumption of water with levels of arsenic =100.0 μg/L was associated with a reduced risk of liver cancer (multivariate-adjusted hazard ratio, 0.29). A higher proportion of individuals exposed to cumulative arsenic level >14,000μg/L× year were carriers of inactive HBV and were positive for HBsAg (60%) than individuals exposed to water below this arsenic level (35%).
Effects of arsenic in drinking water on risk of hepatitis or cirrhosis in persons with and without chronic viral hepatitis. Hsu LI, Wang YH, Hsieh FI et al. Clin Gastroenterol Hepatol. 2016 Apr 6 [Epub ahead of print]
A new study suggests tobacco smoking is not associated with accelerated progression of liver disease in HIV-HCV co-infected individuals.
This is despite it being shown to be an independent risk factor for liver fibrosis in people with HCV.
The study population consisted of participants from the Canadian Co-infection Cohort multi-centre study of HIV/HCV co-infected individuals from 2003 to 2014. Data were analyzed for all participants who did not have significant fibrosis or end-stage liver disease (ESLD) at baseline. Of 1,072 participants, 978 had never smoked, 817 were current smokers, and 161 were previous smokers.
Tobacco exposure was not associated with accelerated progression to significant liver fibrosis nor with ESLD when comparing ever versus never smokers (odds ratios 1.06 and 1.20, respectively) or increases in pack-years smoked (odds ratios 1.05 and 0.94, respectively).
However, the study found that both time-updated alcohol use in the previous six months and presence of detectable HCV ribonucleic acid were associated with aspartate-to-platelet ratio index (APRI) score =1.5.
Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. Costiniuk CT, Brunet L, Rollet-Kurhajec KC et al. Open Forum Infect Dis. 2016 Mar 7;3(2):ofw050 .
Asians with hepatocellular carcinoma (HCC) appear to have a better health-related quality of life (HRQoL) than Europeans with the same condition, new evidence suggests.
In a multinational study, 227 patients with HCC from Asian and European countries completed the EORTC QLQ-C30 and the EORTC QLQ-HCC18 questionnaires.
After adjusting for demographic and clinical characteristics, Asian patients still had significantly better HRQoL scores in emotional functioning, insomnia, (QLQ-C30) and in sexual interest (QLQ-HCC18). Researchers also found an interaction in physical functioning (QLQ-C30) and fatigue (QLQ-HCC18) between geographic region and marital status; married Europeans having worse HRQoL scores than Asian singles.
The researchers suggest cultural differences, as well as clinical differences in the pattern of disease owing to active surveillance of Asian countries may explain the results.
Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Chie WC, Blazeby JM, Hsiao CF et al. Asia Pac J Clin Oncol. 2016 Apr 1 [Epub ahead of print]
Non-alcoholic fatty liver disease (NAFLD) is becoming the principal cause of chronic liver disease across the world and disproportionately affects different ethnic groups in the USA.
That’s according to a literature review of NAFLD and its subtype non-alcoholic steatohepatitis (NASH) from Howard University, Washington, DC.
It also found that, in the US, Hispanics are the most disproportionately affected ethnic group with hepatic steatosis, and elevated aminotransferase levels, whereas African-Americans are the least affected.
Genetic disparities involved in lipid metabolism seem to be the leading explanation for the lowest incidence and prevalence of both NAFLD and NASH in African-Americans.
The reviewers suggest this unprecedented rise requires an initiation of population cohort studies with long-term follow-up to determine the incidence and natural history of NAFLD and it’s under representation in African-Americans. Future studies should also focus on the delineation of the interplay between genetic and environmental factors that trigger the development of NAFLD and NASH.
Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. Sherif ZA, Saeed A, Ghavimi S et al. Dig Dis Sci. 2016 Apr 1. [Epub ahead of print]
In a study at the Cleveland Clinic (1) the combination of sofosbuvir (SOF) and simeprevir (SIM) without riba virin (R) was well tolerated and resulted in high virological response rates in recurrent HCV GT1 infection after liver transplantation (LT).
Sixty-seven patients with HCV GT1 have received SOF+SIM following LT to date: 39% with HCV RNA >6,000,000 IU/mL, 22% with advanced hepatic fibrosis (stage 3-4), 6% with homeostatic recurrence and 58% had previously failed or did not tolerate interferon-based treatments. Mean time from LT to treatment was 6.1 years. All patients had estimated GFR >30 mL/min. Tacrolimus was primary immunosuppression in 84% of patients and minimal immunosuppression dose adjustments were required during treatment.
In intention to treat analysis, 90% achieved end of treatment virologic response and 88% achieved sustained virologic response.
And in a review from the Université Paris Descartes (2), authors wrote that results from clinical studies as well as preliminary real-life data regarding the combination of SOF (a nucleotide polymerase inhibitor) and daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies for HCV, with once-daily oral dosing, a low pill burden, good tolerability, and limited drug-drug interactions, in addition to high antiviral potency, with over 90% sustained virologic response rates.
This combination has high pangenotypic antiviral potency regardless of the severity and patient characteristics. The combination of SOF and an NS5A inhibitor with R for 12 weeks appears to be a very good further treatment option in both cirrhotic and treatment-experienced patients whatever the stage of fibrosis.
Sofosbuvir and simeprevir without ribavirin effectively treat Hepatitis C Virus Genotype 1 infection after liver transplantation in a two-center experience. Jackson WE, Hanouneh M, Apfel T et al.Clin Transplant. 2016 Mar 28 [Epub ahead of print]
Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Pol S, Corouge M, Vallet-Pichard A. Hepat Med. 2016 Mar 4;8:21-26.
New animal research suggests that a high-fat, high-fructose diet may increase the risk and progression of nonalcoholic fatty liver disease (NAFLD).
In a study at Khon Kaen University, Thailand, the effects of a high-fat, high-fructose diet (HFFD) on mRNA levels and activities of the antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were determined in mouse livers and brains.
Histopathology of the liver showed that fat accumulation and inflammation depended on the period of the HFFD-consumption. The levels of mRNA and enzymatic activities of SOD, CAT, and GPx were raised, followed by the increases in malondialdehyde levels in livers and brains of the HFFD mice. The oxidized GSSG content was increased while the total GSH and the reduced GSH were decreased, resulting in the increase in the GSH/GSSG ratio in both livers and brains of the HFFD mice.
A high-fat, high-fructose diet induces antioxidant imbalance and increases the risk and progression of nonalcoholic fatty liver disease in mice. Jarukamjorn K, Jearapong N, Pimson C et al. Scientifica (Cairo) ;2016:5029414
Researchers claimed “promising results” using a sequential combined therapy with entecavir (ETV) and pegylated interferon (PEG-IFN) in young patients with active chronic HBV.
In a study at the University of Turin, 39 patients with different HBV genotypes, HBeAg-positive/negative received a sequential therapy with ETV 0.5 mg/day monotherapy for 12 weeks followed by combination of ETV and PEG-IFN α-2a 180µg/week for 12 weeks, then PEG-IFN monotherapy for 36 weeks.
HBeAg seroconversion rate was 68.2%; HBsAg loss was 33.3%; sustained virological response was 64.1%; primary non-response was observed in eight patients after 12 weeks of PEG-IFN therapy; virological relapse was reported in six patients. Viral genotype and HBsAg decline were the most important predictive factor for PEG-IFN response.
The researchers commented that the stopping rule after 12 weeks of PEG-IFN therapy was useful for identify the non-responders. They added that their results should not be generalized, as further investigations were required for the confirmation of this combination approach.
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. Boglione L, Cariti G, Di Perri G et al. J Med Virol. 2016 Mar 27 [Epub ahead of print]
The high prevalence of viral hepatitis, particularly HBV, in immigrants from Africa represents a challenge for healthcare systems.
The Spanish study highlighted that viral hepatitis is a significant health problem in African countries, from which there has been an increase in the immigrant population.
Researchers at the Hospital de Poniente, El Ejido, studied 2,518 immigrant patients (87.7% Sub-Saharan natives), with a mean age of 31.3 years.
Some 78.8% of the patients had a positive infection marker for HBV, and 638 (25.3%) were diagnosed with active HBV. In 19 cases, antibodies against HDV were detected (four cases with detection of the viral genome). Sixty-eight patients had antibodies against HCV, 26 of whom had a positive viral load.
The researchers concluded this high prevalence of viral hepatitis represent a significant change in the profile of patients treated in Spain, and requires measures aimed at early diagnosis and transmission prevention.
Viral hepatitis and immigration: a challenge for the healthcare system. Cuenca-Gómez JA, Salas-Coronas J, Soriano-Pérez MJ et al. Rev Clin Esp. 2016 Mar 16 [Epub ahead of print]